Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02560389 · ClinicalTrials.gov registry record · Phase 4
Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT02560389 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 103 participants.
The verdict
NCT02560389, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the investigators believe may be affected among women with PTSD. It is hypothesized that L-DOPA may enhance fear extinction learning to a conditioned fear stimulus. If this is true, L-DOPA may improve outcomes for those undergoing certain types of therapy for PTSD, though that aim is beyond the scope of this project. Additionally, the investigators are testing whether an individual's genetic profile affects how well L-DOPA works to enhance cognitive abilities.
Interventions
- DRUG Placebo
- DRUG Levodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02560389
The ClinicalTrials.gov registry entry for NCT02560389 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02560389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02560389 about?
NCT02560389 is a clinical study titled "Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)". The purpose of this study is to investigate a new use for a medication called levodopa (L-DOPA). L-DOPA has been approved for use in Parkinson 's disease, but not for Posttraumatic Stress Disorder (PTSD). L-DOPA is thought to enhance certain cognitive abilities that the investigators believe may be ...
What is the current status of trial NCT02560389?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2016-03. Estimated completion is 2018-05-01.
What interventions are being tested in trial NCT02560389?
The interventions under investigation include: Placebo (DRUG), Levodopa (DRUG).
Who is sponsoring clinical trial NCT02560389?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.